Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In Japan, revenue from the mainstay agrochemical intermediates business declined due to customers' inventory adjustments, shifts in sales timing and other factors. By contrast, export revenue increased on higher sales of pharmaceutical intermediates to Asia. Operating income/loss was affected by the decline in revenue from agrochemical intermediates and persistently high raw material prices.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥923 million (YoY -28.9%) |
| Operating profit | ¥-46 million |
| Ordinary income | ¥9 million (YoY -94.1%) |
| Profit attributable to owners of the parent | ¥-13 million |
| Net income per share | △¥10.03 |
| Equity ratio | End of the current fiscal period 70.4 / End of previous period 68.6 |
| Total assets | ¥12,394 million |
| Net assets | ¥8,725 million |
| Full-year earnings forecast | Net Sales ¥6,500 million (YoY +1.0%) / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Revision to Earnings Forecast | Net Sales ¥6,500 million → ¥6,500 million（0.0%） / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks No change from the most recently disclosed earnings forecast |
| Annual Dividend Forecast | ¥90 → ¥90（0.0%） |
| Regional sales | Domestic ¥796 million (YoY -37.0%) / Exports ¥126 million (YoY +262.4%) |
| Depreciation and amortization | ¥127,556 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥2,727 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 1,373,000 |
| Treasury Shares at Period-End | 66,625 |
| Factors Behind Changes in Business Performance | In Japan, revenue from the mainstay agrochemical intermediates business declined due to customers' inventory adjustments, shifts in sales timing and other factors. By contrast, export revenue increased on higher sales of pharmaceutical intermediates to Asia. Operating income/loss was affected by the decline in revenue from agrochemical intermediates and persistently high raw material prices. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the mainstay agrochemical intermediates business declined significantly due to customers' inventory adjustments and shifts in sales timing, while persistently high raw material prices also contributed to lower earnings. Meanwhile, export revenue increased on higher sales of pharmaceutical intermediates to Asia, and dividend income supported ordinary profit. The earnings forecast will be disclosed at a later date because the impact of the situation in the Middle East remains uncertain, making reasonable forecasting difficult.